Pacific GeneTech (PGT) develops and commercialises novel vaccine and adjuvant technologies focusing on unmet needs in both the veterinary and human market sectors. PGT's core technology is a proprietary platform for low cost orally administered recombinant vaccines against bacterial, viral and parasitic diseases. PGT is located in Hong Kong and in Arkansas, U.S.A.